Article Information
History
- June 19, 2018.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Praneeth R. Kuninty1,
- Ruchi Bansal1,†,
- Sanne W.L. De Geus2,†,
- Jonas Schnittert1,
- Joop van Baarlen3,
- Gert Storm1,4,
- Maarten F. Bijlsma5,6,
- Hanneke W. van Laarhoven7,
- Peter J.K. Kuppen2,
- Alexander L. Vahrmeijer2,
- Arne Östman8,
- Cornelis F.M. Sier2 and
- Jai Prakash1,8,9,*
- 1Department of Biomaterials, Science and Technology, Section: Targeted Therapeutics, Faculty of Science and Technology, University of Twente, The Netherlands
- 2Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
- 3Laboratory Pathology Oost Netherlands (LabPON), Hengelo, The Netherlands
- 4Department of Pharmaceutics, Utrecht University The Netherlands
- 5Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Academic Medical Center and Cancer Center Amsterdam, Amsterdam, The Netherlands
- 6Oncode Institute, Academic Medical Center, Amsterdam. The Netherlands
- 7Department of Medical Oncology, Academic Medical Center and Cancer Center Amsterdam, Amsterdam, The Netherlands
- 8Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
- 9ScarTec Therapeutics BV, Enschede, The Netherlands
- ↵*Corresponding author’s email: j.prakash{at}utwente.nl Corresponding address: Section Targeted Therapeutics, Department of Biomaterials Science and Technology, Faculty of Science and Technology, University of Twente, Zuidhorst 254, 7500 AE Enschede, The Netherlands, T (+31)-53-489 3096
↵† Authors contributed equally